Results 41 to 50 of about 36,254 (205)

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial

, 2020
Aims: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban.
Barco, S., Bauersachs, R. M., Lankeit, M., Otero Candelera, Remedios, Schmidtmann, I., Bernardi, E., Ageno, W., Becattini, C.   +7 more
core   +1 more source

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease [PDF]

, 2017
BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention.
Piegas, LS, Ertl, G, Verhamme, PB, Yusuf, S, Ryden, L, Zhu, J, Metsarinne, KP, Kakkar, AK, Stoerk, S, Keltai, M, Anand, SS, Leong, D, Eikelboom, JW, Misselwitz, F, Branch, KRH, Kim, J-H, Liang, Y, Steg, PG, Yusoff, K, Bosch, J, Connolly, SJ, Lewis, BS, Pogosova, N, Bhatt, DL, O'Donnell, M, Lonn, EM, Widimsky, P, Dagenais, GR, Torp-Pedersen, C, Felix, C, Parkhomenko, AN, Vinereanu, D, Tonkin, AM, Lopez-Jaramillo, P, Fox, KAA, Lanas, F, Hart, RG, Chen, E, Hori, M, Alings, M, Diaz, R, Probstfield, J, Dans, AL, Shestakovska, O, Bruns, NC, Maggioni, AP, Avezum, A, Commerford, PJ, Guzik, TJ   +48 more
core   +7 more sources

Co-Administration of Amiodarone Increases Bleeding by Affecting Rivaroxaban Pharmacokinetics in Patients with Atrial Fibrillation

Pharmaceutics
This study aimed to investigate the impact of the drug–drug interaction between rivaroxaban and amiodarone on the clinical outcomes in patients with non-valvular atrial fibrillation (NVAF), focusing on pharmacokinetic and pharmacodynamic (PK/PD) aspects.
Huamin Ding, Zi Wang, Jia Wang, Yao Yao, Chi Zhang, Houwen Lin, Yong Zhou, Zhichun Gu, Qianzhou Lv, Xiaoye Li   +9 more
doaj   +1 more source

The Effect of Rivaroxaban on CYP4F2 and Transcription Factors’ Activity in HUVECs

Applied Sciences, 2021
Interindividual variabilities between patients taking the anticoagulant rivaroxaban are a result of hepatic metabolism by CYP 450 enzymes. The objective of this study was to evaluate the impact of rivaroxaban on CYP4F2 and transcription factors’ activity
Ieva Ciapiene, Vacis Tatarunas, Agne Giedraitiene, Vaidotas Zvikas, Valdas Jakstas, Audrone Veikutiene, Ugne Meskauskaite, Ugne Venckyte, Audrius Pukalskas, Vaiva Lesauskaite   +9 more
doaj   +1 more source

Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies, Elin Haf Davies, Dyfrig A. Hughes   +2 more
wiley   +1 more source

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE

TH Open, 2017
Background The noninterventional XALIA study compared rivaroxaban with standard anticoagulation for deep vein thrombosis treatment. This substudy describes the demographics, clinical characteristics, and outcomes of the patients with cancer.
Walter Ageno, Lorenzo G. Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Martin van Eickels, Martin Gebel, Alexander G. G. Turpie   +8 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series

British Journal of Clinical Pharmacology, EarlyView.
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno, Berta Torres, Maria Martínez‐Rebollar, Paula Arreba, Octavi Roman, Roger LLobet, Leire Berrocal, Alberto Foncillas, Júlia Calvo, Abiu Sempere, Ivan Chivite, Elisa de Lazzari, Josep Mallolas, Ana González‐Cordón   +13 more
wiley   +1 more source

Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5‐year analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Careful consideration of drug–drug interactions (DDIs) is critical as people with HIV age. We analysed queries submitted to the University of Liverpool HIV Drug Interactions Database to assess changes in prescribing patterns over 5 years. Methods Queries submitted between January 2020 and December 2024 were extracted and categorized by year ...
Cecile Gras, Minh P. Le, Justin Chiong, Sara Gibbons, Daniel Seddon, Catia Marzolini, Saye Khoo   +6 more
wiley   +1 more source

Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation

CJC Open, 2021
Rivaroxaban is commonly used for prevention of thromboembolic diseases in patients with atrial fibrillation. We report a case of an 86-year-old man with hypertension, chronic kidney disease, type 2 diabetes mellitus, dyslipidemia, and atrial fibrillation
Jiaming (Calvin) Liang, MD, MSc, Karanvir Raman, BBA, Siu Him Chan, MD, A. Yashar Tashakkor, MD   +3 more
doaj   +1 more source